EAJF.F VALIRX PLC LS-001
- Market cap
- EUR 660K
- P/E
- -
- P/B
- 0.18x
- ROE
- -78.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is EAJF.F undervalued?
Graham numberThe Graham number of VALIRX PLC LS-001 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
VALIRX PLC LS-001 fundamental analysis
No fundamental analysis for VALIRX PLC LS-001 yet.
VALIRX PLC LS-001 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About VALIRX PLC LS-001
ValiRx plc, together with its subsidiaries, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company develops VAL401, a reformulation of anti-psychotic drug risperidone, which completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer; VAL201, a short peptide, which completed Phase I/II clinical trial for the treatment of prostate cancer; and VAL301, a peptide, which is in pre-clinical t…
Full company profileVALIRX PLC LS-001 financial statements
VALIRX PLC LS-001 annual financial statements (GBP; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 0.00 | 0.00 | 9.60K | 49.8K | 31.4K |
| Gross Profit | - | 0.00 | 8.16K | -13.1K | -6.25K |
| Operating Income | -1.68M | -2.59M | -2.30M | -2.14M | -1.82M |
| EBITDA | - | -2.38M | -2.04M | -1.86M | -2.18M |
| Net Income | -1.52M | -2.37M | -2.04M | -1.92M | -2.23M |
| EPS | -0.02 | -0.03 | -0.02 | -0.01 | 0.00 |
| Balance Sheet | |||||
| Total Assets | 3.52M | 3.98M | 3.13M | 4.26M | 2.63M |
| Total Liabilities | 110K | 150K | 227K | 346K | 235K |
| Shareholders' Equity | 3.60M | 4.05M | 3.22M | 4.32M | 2.86M |
| Cash & Short-term Investments | 594K | 1.14M | 175K | 1.56M | 792K |
| Cash Flow | |||||
| Operating Cash Flow | -1.26M | -1.71M | -1.77M | -1.58M | -1.51M |
| Capital Expenditure | 0.00 | 0.00 | 306K | 38.2K | 13.6K |
| Free Cash Flow | -1.26M | -1.71M | -2.08M | -1.62M | -1.52M |
| Ratios | |||||
| ROE | -42.2% | -58.4% | -63.3% | -44.4% | -78.2% |
| ROA | -43.1% | -59.5% | -65.1% | -44.9% | -84.8% |
| Net Profit Margin | - | - | -21,226.1% | -3,848.7% | -7,115.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
VALIRX PLC LS-001 dividends
VALIRX PLC LS-001 has not paid dividends in the last 6 fiscal years.
Last stock split: 1:125 on Apr 6, 2020.
Who owns VALIRX PLC LS-001
- Insiders 8.77%
- Institutions 0.00%
- Public & others 91.23%
- Shares outstanding 1.32B
- Free float 789M
VALIRX PLC LS-001 company profile
- Company name
- VALIRX PLC LS-001
- Ticker
- EAJF.F
- ISIN
- GB00BLH13C52
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 11
- Fiscal year end
- December
- Address
- 20 Wenlock Road, London, United Kingdom, N1 7GU
- Phone
- 44 115 7840026
- Website
- valirx.com
About VALIRX PLC LS-001
ValiRx plc, together with its subsidiaries, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company develops VAL401, a reformulation of anti-psychotic drug risperidone, which completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer; VAL201, a short peptide, which completed Phase I/II clinical trial for the treatment of prostate cancer; and VAL301, a peptide, which is in pre-clinical trial for the treatment of endometriosis. It is also involved in the development of BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment of SARS-CoV2 infection; and CLX001, a peptide in a nanoparticle formulation for the treatment of triple negative breast cancer. The company was founded in 2006 and is based in London, the United Kingdom.
VALIRX PLC LS-001 management
5- Dr. Mark Edward Eccleston M.B.A., Ph.D.CEO, Member of Scientific & Commercial Advisory Board and Director · born 1971
- Mr. James Gerry Desler FCACFO, Company Secretary & Executive Director · born 1945
- Mr. Kumar NawaniHead of Operations
- Mr. Mark TreharneCorporate Development Manager
- Dr. Andrew CarnegieHead of Strategic Commercial Development